Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
Onconic Therapeutics Inc.
Onconic Therapeutics Inc.
Boehringer Ingelheim
Mayo Clinic
M.D. Anderson Cancer Center
Astellas Pharma Inc
University of Pennsylvania
Boehringer Ingelheim
Duke University
British Columbia Cancer Agency
Washington University School of Medicine
Case Comprehensive Cancer Center
City of Hope Medical Center
University of California, San Francisco
Case Comprehensive Cancer Center
University of Pennsylvania
Thomas Jefferson University
Fox Chase Cancer Center
Fudan University
NHS Greater Glasgow and Clyde
Nelum Corp
Mateon Therapeutics
The First Affiliated Hospital with Nanjing Medical University
Rutgers, The State University of New Jersey
Adenocyte, LLC
First Affiliated Hospital of Chongqing Medical University
Sixth Affiliated Hospital, Sun Yat-sen University
University of Malaya
Fudan University
Karolinska University Hospital
Ruijin Hospital
Peking Union Medical College Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
University Health Network, Toronto
University of Washington
Ruijin Hospital
First People's Hospital of Hangzhou
Peking University Third Hospital
Ruijin Hospital
Linkoeping University
The Third Xiangya Hospital of Central South University
Tongji Hospital
Ambry Genetics
Abramson Cancer Center at Penn Medicine
Campus Bio-Medico University
Wakayama Medical University
Azienda USL Reggio Emilia - IRCCS
Yonsei University
Peking University Third Hospital
Wakayama Medical University
National Taiwan University Hospital